Amarin logo 3 Biotech Stocks Gaining Momentum Amarin (NASDAQ:AMRN) executives told investors that 2025 marked a “substantial achievement” year as the company advanced a strategic pivot toward a more partnered international commercial model and executed a global restructuring aimed at lowering its operating expense base. On the company’s fourth-quarter and full-year 2025 earnings call, management highlighted a new long-term agreement with Recordati to commercialize VAZKEPA in Europe, ongoing efforts to ...